August 2022

Advancing Cancer Care Equity: Yes, and…

ByJoseph Alvarnas, MD

August 18th 2022

Takeda Partnership With Xavier University Seeks Blueprint to Advance Health Equity

ByMary Caffrey

August 18th 2022

NPC Weighs in on PBM Inquiry; Radiologist Receives Award; OneOncology Creates Disease Groups

ByAJMC Staff

August 17th 2022

News from Strategic Alliance Partners of The American Journal of Managed Care®.

Trilaciclib Before Chemotherapy May Prevent Hematological Events—With Savings

ByMary Caffrey

August 16th 2022

Shifting Landscape of Care Delivery Is Impacting Value-Based Cancer Care

ByLaura Joszt, MA

August 16th 2022

The Institute for Value-Based Medicine series visits Texas Oncology in Austin.

How Advocacy Groups and Patient Data Can Help Drive Health Equity

ByAdam Mariano, Esq, MSPH

August 15th 2022

Taking Action to Address Health Equity in Oncology

BySusan Shiff, PhD, MBA

August 15th 2022

New Enhancing Oncology Model Builds on Knowledge From the OCM

ByStuart Staggs, MSIE

August 15th 2022

OCM Successor Puts Focus on Equity in Cancer Care—With Fewer Dollars for Services

ByMary Caffrey

August 15th 2022

Defining Appropriate Quality Performance Metrics for Pharmacies Dispensing Oral Oncology Therapies

ByNatasha Khrystolubova, BPharm, RPh, BCOP,Ray Bailey, RPh,Roger Orr, PharmD, BCOP,Lucio Gordan, MD,Trista Auger, RPhT, CPhT

August 11th 2022

A Call to Action: Oncology Practices—and Patients—Need Performance Measures for Managing Oral Therapies

ByNatasha Khrystolubova, BPharm, RPh, BCOP,Ray Bailey, RPh,Roger Orr, PharmD, BCOP,Lucio Gordan, MD,Trista Auger, RPhT, CPhT

August 11th 2022

Zelenetz Discusses How to Evaluate Responses to Therapy in DLBCL

ByAJMC Staff

June 22nd 2022

Andrew Zelenetz, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, is the current chair of the Non-Hodgkin Lymphoma Guidelines panel of the National Comprehensive Cancer Network (NCCN).

Addressing Cancer Health Disparities in a Multilateral Collaboration in an Independent Community Cancer Clinic: Translating Words Into Action

ByKashyap Patel, MD,Hirangi Mukhi, BS,Anjana Patel, BSc,Niyati Nathwani, MD,Dhwani Mehta, MS,Jennifer Sherak, MBA,Natasha Clinton, MSN, APRN, AOCNP,Holly Pisarik, JD,Benjamin Brown, BS,Sara Rogers, PharmD,Mary Kruczynski,Nicolas Ferreyros, BA,Ted Okon, MBA

March 15th 2022

No One Left Behind, a program to provide financial assistance and access to cancer care at Carolina Blood and Cancer Care Associates in South Carolina, will be discussed during a session of the Community Oncology Alliance 2022 Community Oncology Conference.

Patel et al, Appendix B

March 15th 2022

August 2022

Advancing Cancer Care Equity: Yes, and…

Takeda Partnership With Xavier University Seeks Blueprint to Advance Health Equity

NPC Weighs in on PBM Inquiry; Radiologist Receives Award; OneOncology Creates Disease Groups

Trilaciclib Before Chemotherapy May Prevent Hematological Events—With Savings

Shifting Landscape of Care Delivery Is Impacting Value-Based Cancer Care

How Advocacy Groups and Patient Data Can Help Drive Health Equity

Taking Action to Address Health Equity in Oncology

New Enhancing Oncology Model Builds on Knowledge From the OCM

OCM Successor Puts Focus on Equity in Cancer Care—With Fewer Dollars for Services

Defining Appropriate Quality Performance Metrics for Pharmacies Dispensing Oral Oncology Therapies

A Call to Action: Oncology Practices—and Patients—Need Performance Measures for Managing Oral Therapies

Zelenetz Discusses How to Evaluate Responses to Therapy in DLBCL

Addressing Cancer Health Disparities in a Multilateral Collaboration in an Independent Community Cancer Clinic: Translating Words Into Action

Patel et al, Appendix B

Patel et al Appendix A

Trending on AJMC

Tozorakimab Benefits Current and Former Smokers: Frank Sciurba, MD

FDA Clears First Alzheimer Blood Test for Adults as Young as 40

RSV Vaccine Shows 100% Effectiveness in COPD: Jorgen Vestbo, MD

5 Things to Know About the 2026 ESC Heart Failure Guidelines

Enlicitide, Oral PCSK9 Inhibitor, Cuts LDL 60% in CORALreef Trials